GlassScriptPhysician profile
Barbara Griffith
NPI 1063568921
$2,671.18
in general payments reported to CMS, 2019-2025
28 companies · $22.05 in 2025
The $22.05 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,017 · 2020: $573 · 2021: $441 · 2022: $410 · 2023: $71.21 · 2024: $137 · 2025: $22.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $230.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $416.20 | 2020-2024 | Ozempic |
| Merck Sharp & Dohme LLC | $280.71 | 2019-2021 | |
| Glaxosmithkline, LLC. | $214.09 | 2019-2022 | |
| Abbvie INC. | $177.71 | 2021-2022 | |
| Gilead Sciences, INC. | $156.08 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $134.81 | 2019 | |
| Amarin Pharma, INC. | $127.88 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $124.95 | 2019 | |
| Horizon Therapeutics Plc | $117.15 | 2019-2022 | |
| Abbott Laboratories | $111.79 | 2021-2022 | |
| Allergan, INC. | $104.63 | 2019-2020 | |
| Pfizer INC. | $91.80 | 2019-2022 | |
| Amgen INC. | $88.28 | 2020-2024 | Otezla, Repatha |
| Lilly USA, LLC | $75.90 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $74.34 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $62.55 | 2024-2025 | Voquezna |
| Neuronetics, INC. | $59.52 | 2019 | |
| Alkermes, INC. | $43.37 | 2022 | |
| Janssen Pharmaceuticals, INC | $40.66 | 2019-2021 | |
| Genentech USA, INC. | $36.42 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.53 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.05 | 2022 | |
| Alfasigma USA, INC. | $18.89 | 2021 | |
| Tactile Systems Technology INC | $18.54 | 2019 | |
| Phadia US INC. | $17.29 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.70 | 2019 | |
| Redhill Biopharma INC. | $11.55 | 2020 | |
| Forte Bio-Pharma LLC | $10.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.